Showing 3971-3980 of 9301 results for "".
- Allergan Aesthetics Introduces CoolSculpting Elitehttps://practicaldermatology.com/news/allergan-aesthetics-introduces-coolsculpting-elite/2460667/Allergan Aesthetics, an AbbVie company, is launching CoolSculptingElite, its next generation fat reduction system with applicators designed to complement the body's natural curves. The system will launch with a new applicator collection, which includes seven different shapes and sizes. The innova…
- Arcutis Moves Another Candidate Into Phase 3 Trialshttps://practicaldermatology.com/news/arcutis-moves-another-candidate-into-phase-3-trials/2460664/Roughly a week after announcing plans to initiate Phase 3 clinical trials for topical roflumilast cream (ARQ-151) in the treatment of atopic dermatitis (AD), Arcutis Biotherapeutics, Inc. is now doing the same for topical roflumilast foam (ARQ-154) for seborrheic dermatitis following an End-of-Pha…
- MyHealthTeams' "Gaining Control with Psoriasis" Challenge Empowers Psoriasis Patients to Change Things Uphttps://practicaldermatology.com/news/myhealthteams-gaining-control-with-psoriasis-challenge-empowers-psoriasis-patients-to-change-things-up/2460663/MyHealthTeams is launching the "Gaining Control with Psoriasis" Challenge. This new resource center, integrated into the MyPsoriasisTeam social network experience and developed in partnership with AbbVie Medical Affairs, is designed to empower people facing psoriasis to improve their physical a…
- LEO Pharma Data: Tralokinumab Benefits Adult ADhttps://practicaldermatology.com/news/leo-pharma/2460662/Results from a post-hoc subanalysis of the Phase 3 ECZTRA 3 trial demonstrate the potential for LEO Pharma’s tralokinumab as a treatment for adults with moderate-to-severe atopic dermatitis. Investigational tralokinumab has not yet been approved by any regulatory authority. The data, shared virt…
- Novartis: Ligelizumab Receives Breakthrough Therapy Designation in CSUhttps://practicaldermatology.com/news/novartis-ligelizumab-receives-breakthrough-therapy-designation-in-csu/2460656/Ligelizumab from Novartis now has Breakthrough Therapy designation from FDA for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment. Ligelizumab (QGE031) is currently bein…
- New Merz and Candela Collab Announcedhttps://practicaldermatology.com/news/new-merz-candela-collab-announced/2460655/Merz Aesthetics and Candela Corporation are joining forces. As part of the collab, sales representatives from each company will now have the ability to promote products from both organizations. The companies are not formally changing their structure or formally integrating service. Each company w…
- Fitness Level Tied to Psoriasis Riskhttps://practicaldermatology.com/news/fitness-level-tied-to-psoriasis-risk/2460653/Low fitness levels may increase risk for psoriasis, according to a register-based study of military recruits. Specifically, male recruits to compulsory military training who were rated as the least fit had a 35 percent higher risk for psoriasis when compared to the fittest recruits. The study was…
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine. In two of these ca…
- NRS Awards 2020 Research Grantshttps://practicaldermatology.com/news/nrs-awards-2020-research-grants/2460622/Expect to learn more about the genome of the Demodex mite, the microbiome’s role in rosacea, and the skin and eyelid lipid content of individuals with rosacea.The National Rosacea Society has awarded funding for studies—two new, plus continuing support for one ongoing study—into these topics as par…
- Merz Aesthetics Calls for Entries for First-Ever Innovation Forumhttps://practicaldermatology.com/news/merz-aesthetics-calls-for-entries-for-first-ever-innovation-forum/2460618/Merz Aesthetics is launching its first-ever Innovation Forum with a call for abstract submissions seeking the most creative and inventive medical aesthetics abstracts from the next generation of researchers and healthcare professionals. The author of the winning abstract will have the opportuni…